Emergent Biosolutions has set out to capture a share of the expanding viral vector and gene therapy sector.
The US countermeasures developer said it will spend $75 million to add viral vector and gene therapy manufacturing capacity at a facility in Canton, Massachusetts.
At present the plant – which was acquired from Sanofi in 2017 – produces drug substance for live viral vaccines, including Emergent’s smallpox jab ACAM2000.
{iframe}https://bioprocessintl.com/bioprocess-insider/emergent-to-add-gene-therapy-capacity-through-75m-plant-expansion/{/iframe}